PSI, CURB-65, SMART-COP or SCAP? And the winner is... SMART DOCTORS  by Froes, Filipe
Rev Port Pneumol. 2013;19(6):243--244
www.revportpneumol.org
EDITORIAL
PSI,  CURB-65,  SMART-COP  or  SCAP?  And  the  winner  is...  SMART
DOCTORS o  
b
C
p
f
p
i
w
(
2
H
j
A
n
b
t
S
i
s
(
c
(
o
u
f
s
c
r
c
T
and  serious  progressive  complications,  cutting  down  costsPSI,  CURB-65,  SMART-COP  ou  SCAP?  E
Community-acquired  pneumonia  (CAP)  is  one  of  the  most
common  diseases  in  adults  with  an  estimated  average  annual
incidence  of  5  to  11  cases  per  1000  inhabitants,1 which
increases  signiﬁcantly  with  age.2 It  is  a  major  cause  of  hos-
pital  admission  but  the  percentage  of  patients  hospitalized
for  CAP  varies  greatly  depending  on  country  or  region,  the
populations  studied  and  the  way  the  health  systems  are
organised.  In  Portugal,  it  is  estimated  that  25  to  50%  of
adults  with  CAP  are  admitted  to  hospital3 and,  in  the  period
from  2000  to  2009,  CAP  was  one  of  the  principle  causes
of  hospitalization,  representing  3,7%  of  total  adult  hospital
admissions.4
Although  the  majority  of  patients  are  treated  as  out-
patients,  hospital  admissions  for  treatment  of  patients  with
CAP  represent  a  big  percentage  of  the  cost  of  treating  CAP
patients.  Studies  carried  out  in  the  United  States  of  Amer-
ica  (USA),  at  the  end  of  the  last  century,  worked  out  that
the  total  annual  cost  was  8,4  billion  US  dollars,  of  which  8,0
billion  (95%)  was  the  result  of  hospital  admission.5 To  deal
with  this,  Michael  Fine  et  al  developed  the  ﬁrst  score  for
CAP,  the  Pneumonia  Severity  Index  (PSI),  with  the  goal  of
predicting  mortality  and  identifying  patients  at  low  risk  of
mortality  who  did  not  need  to  be  admitted  to  hospital.6 The
PSI  stratiﬁes  patients  into  5  risk  classes,  based  on  evalua-
tion  of  more  than  twenty  clinical  and  laboratory  parameters,
heavily  weighted  for  age  and  comorbidities.7 The  complex-
ity  of  the  PSI,  led  to  the  development  of  another  score,
the  CURB-65  (acronym  for  Confusion,  Urea,  Respiratory  rate,
Blood  pressure  and  age  ≥65)  by  the  British  Thoracic  Society.8
Various  studies  have  evaluated  the  PSI  and  the  CURB-65  in
the  same  populations  with  comparable  results  for  predicting
mortality  and  identifying  low-risk  patients,  although  in  one
study  the  CURB-65  had  better  results  in  predicting  mortality
in  the  most  serious  cases.7
It  should  be  pointed  out  that  neither  the  PSI  nor  the
CURB-65  were  developed  to  identify  patients  needing  to
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e  referred  to  the  Intensive  Care  Units  (ICU),  although  the
URB-65  does  appear  to  be  more  precise  than  the  PSI  in
redicting  admission  to  ICU.9
In  2001,  the  American  Thoracic  Society  (ATS)  made  the
ollowing  recommendations  for  CAP  in  order  to  identify
atients  with  serious  pneumonia  and  predicted  admission
nto  ICU  using  major  and  minor  criteria.10 Severe  CAP
as  deﬁned  by  the  presence  of  one  of  two  major  criteria
dependence  on  mechanical  ventilation  or  septic  shock)  or
 of  three  minor  criteria  (systolic  blood  pressure  ≤90  mm
g,  multilobar  involvement  or  PaO2/FIO2 ≤250).10 In  2007,
oint  recommendations  by  the  Infectious  Diseases  Society  of
merica  (IDSA)  and  the  ATS11 increased  the  minor  criteria  to
ine,  patients  needing  to  meet  at  least  3  minor  criteria  to
e  deﬁned  as  severe  CAP;  however,  there  were  no  gains  in
erms  of  sensitivity  or  speciﬁcity  over  the  2001  criteria.12
More  recently,  two  new  scores  have  emerged:  the
MART-COP  (acronym  for  Systolic  blood  pressure,  Multilobar
nﬁltrates,  Albumin,  Respiratory  rate,  Tachycardia,  Confu-
ion,  Oxygen  and  pH)  developed  in  Australia,13 and  SCAP
Severe  CAP)  developed  in  Spain,14 which  utilizes  major
riteria  (pH  and  systolic  blood  pressure)  and  minor  ones
confusion,  urea,  respiratory  rate,  multilobar  inﬁltrates,
xygen  and  age  ≥80).  Although  many  of  the  parameters  eval-
ated  are  common  to  all  scores,  these  two  new  scores  differ
rom  the  PSI  and  CURB-65  in  that  they  do  not  present  the
ame  level  of  validation  and  their  principle  goal  is  identiﬁ-
ation  of  patients  with  severe  pneumonia  who  need  to  be
eferred  to  ICU.  In  the  actual  PJP  edition  C.  Ribeiro  et  al.
ompare  these  new  scores  with  the  two  previous  ones.15
All  the  existing  scores  have  advantages  and  limitations.
he  main  advantages  are  the  prediction  of  risk  of  mortality06
y  reducing  expensive  hospital  human  resources  on  low-risk
atients  and  in  the  early  recognition  of  the  most  seriously  ill
atients  so  that  they  beneﬁt  from  rapid  referral  to  the  ICU.7
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nother  important  advantage  is  the  use  of  scores  in  clini-
al  research.7 In  terms  of  limitations,  the  different  scores
ary  in  terms  of  levels  of  validation  and  accuracy,  partic-
larly  among  certain  age  groups,  such  as  the  oldest  and
he  youngest.  They  do  not  properly  take  into  account  social
actors  and  the  degree  of  dependency  which  could  affect
he  decision  as  to  whether  to  admit  to  hospital  and  there
s  also  the  omission  of  important  comorbidities  like  DPOC,
mmunosuppression  and  functional  status.  Very  recently  the
nﬂuenza  A(H1N1)  pandemic  in  2009,  provided  the  opportu-
ity  to  check  the  lowest  predictive  value  and  usefulness  of
he  different  scores  in  patients  with  viral  pneumonia.16
None  of  the  current  scores  include  acute  phase  inﬂam-
atory  markers  or  biomarkers  but  preliminary  data  indicate
hat  these,  in  particular  procalcitonin,  could  improve  the
core  risk  stratiﬁcation  and  thus  increase  their  usefulness.7
In  conclusion,  these  scores  are  useful  tools  but  they
annot  nor  should  they  substitute  medical  evaluation  and
linical  reasoning.  Ideally,  the  best  strategic  approach  to
AP  will  always  depend  on  experienced  doctors  (SMART-
OCTORS)  who  can  apply  their  knowledge  to  the  complexity
nd  speciﬁc  characteristics  of  the  individual  patients  and
an  use  the  scores  as  supplementary  information  to  make
ppropriate  decisions  for  the  population  in  question.
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